Patents by Inventor Peter J. Tontonoz

Peter J. Tontonoz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210255205
    Abstract: The present disclosure relates to compositions and methods for modulating a subject's cholesterol levels and/or treating disorders related to high cholesterol.
    Type: Application
    Filed: June 27, 2019
    Publication date: August 19, 2021
    Inventors: Peter J. Tontonoz, Jaspreet S. Sandhu
  • Publication number: 20140072580
    Abstract: In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided.
    Type: Application
    Filed: July 15, 2013
    Publication date: March 13, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter J. Tontonoz, Noam Zelcer
  • Patent number: 8512964
    Abstract: In certain embodiments this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: August 20, 2013
    Assignee: The Regents of the University of California
    Inventors: Peter J. Tontonoz, Noam Zelcer
  • Publication number: 20110318367
    Abstract: In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided.
    Type: Application
    Filed: December 11, 2009
    Publication date: December 29, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter J. Tontonoz, Noam Zelcer
  • Publication number: 20020137794
    Abstract: In accordance with the present invention, it has been discovered that retinoic acid receptor (RAR) antagonists are capable of modulating processes mediated by other members of the steroid/thyroid hormone receptor superfamily, including permissive receptors such as PPARs (e.g., PPAR&agr;, PPAR&dgr; and PPAR&ggr;). Indeed, it has been discovered that RAR antagonists, in combination with agonists for members of the steroid/thyroid hormone receptor superfamily, are capable of inducing and/or enhancing processes mediated by such members.
    Type: Application
    Filed: July 13, 1999
    Publication date: September 26, 2002
    Inventors: RONALD M. EVANS, PETER J. TONTONOZ, LASZLO NAGY
  • Patent number: 6436993
    Abstract: In accordance with the present invention, it has been discovered that retinoic acid receptor (RAR) antagonists are capable of modulating processes mediated by other members of the steroid/thyroid hormone receptor superfamily, including permissive receptors such as PPARs (e.g., PPAR&agr;, PPAR&dgr; and PPAR&ggr;). Indeed, it has been discovered that RAR antagonists, in combination with agonists for members of the steroid/thyroid hormone receptor superfamily, are capable of inducing and/or enhancing processes mediated by such members.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: August 20, 2002
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Peter J. Tontonoz, Laszlo Nagy